Gain Capital Holdings, Vail Resorts, Johnson & Johnson, Alkermes and Alexion Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

Zacks

For Immediate Release

Chicago, IL – March 24, 2014– Zacks Equity Research highlights Gain Capital Holdings (GCAP-Free Report) as the Bull of the Day and Vail Resorts (MTN-Free Report) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Johnson & Johnson (JNJ-Free Report), Alkermes (ALKS-Free Report) and Alexion Pharmaceuticals (ALXN-Free Report).
 
Here is a synopsis of all five stocks:

Bull of the Day:

Gain Capital Holdings (GCAP-Free Report) has been posting some impressive positive earnings surprises lately and they have shown some significant revenue growth. Analysts have moved estimates higher and that makes this stock a Zacks #1 Rank (Strong Buy), and today it is the Bull of the Day.
 
There has been a healthy amount of data pointing to the return of the retail customer. The market alienated a lot of people when it imploded on itself a few years ago during the financial crisis, but they look to be coming back.
 
GCAP has seen some steady progress in the growth of funded customer accounts lately and is poised to see more growth. What is really key is over the last two quarters, where account growth slowed, asset growth picked up. The translation here is that the customers have been making money... or adding cash to their accounts.
 
Gain Capital Holdings provides trading services and solutions to retail and institutional customers worldwide. It specializes in global over-the-counter (:OTC) markets, including spot foreign exchange (forex), precious metals, and contracts-for-difference (CFDs). The company operates FOREX.com, which enables its retail customers to access global OTC financial markets, including forex, precious metals, and CFDs on commodities and indices.
 
Has been crushing the number lately. The last three quarters have seen positive earnings surprises of 69%, 44% and 85% respectively. Those are some solid beats of the Zacks Consensus Estimate.
 
What really caught my eye was the positive revenue surprises. Not only is the company beating the bottom line in impressive fashion, but they are doing the same thing on the top line too. The last three quarters have seen positive revenue surprises of 25%, 21% and 14% respectively.

Bear of the Day:

Vail Resorts (MTN-Free Report) has only one beat of the Zacks Consensus Estimate over the last five quarters. Recently a big miss on top and bottom has pushed analysts to lower earnings estimates. That has made this stock a Zacks #5 Rank (Strong Sell), and today it is the Bear of the Day.

This has been a heck of a winter. Lots of snow and lots of cold. Those super cold stretches might have actually hurt ski resorts more than they helped them. Yes, there was plenty of snow, but when the mercury falls that low, people tend to stay inside.
 
Vail Resorts, Inc. operates in three segments: Mountain, Lodging, and Real Estate. The Mountain segment operates eight ski resort properties, including the Vail Mountain, Breckenridge Ski, Keystone, Beaver Creek, Heavenly Mountain, Northstar, Kirkwood Mountain, and Canyons resorts. Vail Resorts, Inc. was founded in 1997 and is based in Broomfield, Colorado.
 
As noted already, MTN has missed the Zacks Consensus Estimate in four of the last five quarters. The most recent miss was a big one, coming in $0.31 light of the mark for a 16% negative earnings surprise. The company also missed on the topline too.
 
Additional content:

Good News for Johnson & Johnson
 
Johnson & Johnson (JNJ-Free Report) halted an early phase III study (n=509) on a three-month formulation of Invega Sustenna (paliperidone palmitate) on recommendation of an Independent Data Monitoring Committee (:IDMC). The IDMC also recommended Johnson & Johnson to unblind data from the study based on certain positive efficacy results.
 
The international, randomized, multicenter, double-blind study was evaluating the efficacy of the three-month formulation of Invega Sustenna in delaying time to first occurrence of relapse of symptoms of schizophrenia in adults compared to placebo. The patients in the study were initially randomized with the one-month formulation of Invega Sustenna after which they received the three-month formulation.
 
We note that the one-month formulation of Invega Sustenna is already approved for the treatment of schizophrenia. The one-month formulation utilizes Alkermes' (ALKS-Free Report) proprietary NanoCrystal technology enabling solubility of poorly water-soluble compounds.
 
The IDMC’s recommendation was based on certain pre-specified criteria from the phase III study. Invega Sustenna achieved a statistically significant difference in delaying time to relapse based on the interim analysis after 60% (42 events) of the projected relapses occurred compared to placebo.
 
Johnson & Johnson intends to file a New Drug Application (:NDA) in the U.S. for the three-month formulation of Invega Sustenna by year end following final analysis of the study results and discussions with the U.S. regulatory body.
 
We note that Johnson & Johnson is already well established in the schizophrenia market with products like the one-month formulation of Invega Sustenna and Risperdal Consta. The products together contributed around $2.6 billion in 2013. In the event of the three-month formulation of Invega Sustenna getting approved, Johnson & Johnson will strengthen its position in the market further.
 
Johnson & Johnson currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Alexion Pharmaceuticals (ALXN-Free Report), which carries a Zacks Rank #1 (Strong Buy).
 
Get today’s Zacks #1 Stock of the Day with your free subscription to Profit from the Pros newsletter:
 
About the Bull and Bear of the Day
 
Every day, the analysts at Zacks Equity Research select two stocks that are likely to outperform (Bull) or underperform (Bear) the markets over the next 3-6 months.
 
About the Analyst Blog
 
Updated throughout every trading day, the Analyst Blog provides analysis from Zacks Equity Research about the latest news and events impacting stocks and the financial markets.
 
About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
 
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Click here to subscribe to this free newsletter today.
 
About Zacks
 
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros.  In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
 
Get the full Report on GCAP - FREE
Get the full Report on MTN - FREE
Get the full Report on JNJ - FREE
Get the full Report on ALKS - FREE
Get the full Report on ALXN - FREE
 
Follow us on Twitter:  http://twitter.com/zacksresearch
 
Join us on Facebook:  http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
 
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

 
Zacks.com provides investment resources and informs you of these resources, which you may choose to use in making your own investment decisions. Zacks is providing information on this resource to you subject to the Zacks "Terms and Conditions of Service" disclaimer. www.zacks.com/disclaimer.
 
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Read the analyst report on GCAP

Read the analyst report on MTN

Read the analyst report on JNJ

Read the analyst report on ALKS

Read the analyst report on ALXN


Zacks Investment Research

View Comments (0)